The IPO Buzz: BioAge Labs Upsizes IPO to Raise $189 Million – Up 40% – Before Pricing
BioAge Labs (BIOA Proposed), a Phase II biotech developing an anti-obesity drug, upsized its IPO early today by increasing the number of shares to 10.5 million – up from 7.5 million originally – according to an S-1/A filing dated Sept. 25, 2024. That’s a 40 percent increase. BioAge Labs now expects to raise $189 million – […]
September 25, 2024 Read More